Investment Type: Venture Capital
Mentions in press and media 14
| Date | Title | Description |
| 28.07.2024 | CatalYm's $150 Million Bet on Cancer Resistance: A New Dawn in Immunotherapy | In the relentless battle against cancer, CatalYm has emerged as a beacon of hope. The Munich-based company recently secured $150 million in Series D funding, a significant leap forward in its mission to combat cancer therapy resistance. Thi... |
| 27.07.2024 | CatalYm: Cancer Therapy Resistance Mechanism Company Raises $150 Million In Series D | CatalYm announced the completion of a $150 million Series D financing. The oversubscribed funding round was led by new investors, Canaan Partners and Bioqube Ventures, and joined by Forbion’s Growth Opportunities Fund, Omega Funds and Gilde... |
| 09.06.2022 | Amaroq Therapeutics hits early milestones and makes key appointments to Scientific Advisory Board | Promising 'dark matter' cancer therapy has clinical trials in sight DUNEDIN, New Zealand, June 9, 2022 /PRNewswire/ -- Amaroq Therapeutics, a biotechnology company focussed on developing a new class of therapeutics that target lncRNA in can... |
| 15.06.2021 | ENA Respiratory Advances COVID-19 Preventative Therapy through AU$32 Million Funding Round | Round jointly led by Brandon Capital and Minderoo Foundation with co-investment from Uniseed will support the clinical development of INNA-051 Company appoints President and Chief Scientific Officer of the COPD Foundation and respiratory th... |
| 28.09.2020 | Preventative nasal spray shown to reduce viral replication by up to 96% in COVID-19 challenge study | New preventative nasal spray treatment that could protect people from COVID-19 infection and prevent transmission announced Novel therapy developed by Australian biotech company, Ena Respiratory, shown to significantly reduce COVID-19 virus... |
| 12.06.2020 | Glyscend Therapeutics Completes $20.5 M Series A | Glyscend Therapeutics, a privately held biopharmaceutical company developing novel treatments for type 2 diabetes (T2D) and related metabolic conditions, today announced the closing of a $20.5 million Series A financing round. Healthcare in... |
| 08.01.2016 | Australian Brandon Capital Partners Expands Operations into the United States | Brandon Capital Partners, an Australian life science venture capital firm, expanded its operations into the United States. The firm opened a Palo Alto office which will be led by Venture Partner J. Leighton Read, MD, an industry veteran and... |
| 21.04.2015 | Brandon Capital Closes Life Science Venture Capital Fund at AU$200M | Brandon Capital, an Australian life science venture capital firm, closed a fund for the Medical Research Commercialisation Fund (MRCF), at AU$200m. MRCF3, which will be Australia’s largest ever life science venture fund, is supported by exi... |
| 23.10.2014 | Auspherix Secures AU$1M in Series A Financing | Auspherix Pty Ltd, a Sydney, Australia-based early stage anti-infectives company developing novel antibiotics to treat resistant bacterial disease, secured a further AU$1m in Series A financing. Australia’s Medical Research Commercialisatio... |
| 03.12.2013 | Auspherix Launches with AU$1M in Financing | Auspherix, an Australian early stage anti-infectives company, launched with AU$1m in financing. The company will in-license intellectual property from the ithree institute at the University of Technology Sydney (UTS), emerging from research... |
Show more